Fox Run Management L.L.C. Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Fox Run Management L.L.C. invested approximately $252,000 in Kiniksa Pharmaceuticals International, acquiring 11,352 shares during the first quarter.
• Several hedge funds, including Russell Investments Group Ltd. and Nuveen LLC, also significantly increased their stakes in Kiniksa during the same period, indicating growing institutional interest in the company.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, surpassing analyst expectations and contributing to a positive outlook with a consensus price target of $41.17 among analysts.

Fox Run Management L.L.C. purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 11,352 shares of the company's stock, valued at approximately $252,000.

Several other institutional investors and hedge funds have also bought and sold shares of KNSA. Nuveen LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $16,992,000. Braidwell LP lifted its holdings in Kiniksa Pharmaceuticals International by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after buying an additional 557,934 shares during the period. Millennium Management LLC lifted its holdings in Kiniksa Pharmaceuticals International by 50.9% in the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock worth $15,422,000 after buying an additional 263,146 shares during the period. Deutsche Bank AG lifted its holdings in Kiniksa Pharmaceuticals International by 177.1% in the 1st quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after buying an additional 252,125 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $3,955,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Finally, Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $41.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 62,116 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $27.33, for a total transaction of $1,697,630.28. Following the completion of the transaction, the chief executive officer owned 96,674 shares in the company, valued at approximately $2,642,100.42. The trade was a 39.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the sale, the insider directly owned 57,403 shares of the company's stock, valued at approximately $1,868,467.65. The trade was a 33.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 674,849 shares of company stock valued at $21,144,188 in the last ninety days. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded up $0.17 on Friday, reaching $33.75. The stock had a trading volume of 356,168 shares, compared to its average volume of 705,288. The company has a 50-day simple moving average of $29.78 and a 200-day simple moving average of $25.53. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of 843.96 and a beta of 0.14. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $34.55.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.